Lorlatinib
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-Small-Cell Lung Cancer
Conditions
Non-Small-Cell Lung Cancer, NSCLC
Trial Timeline
Dec 28, 2021 → Dec 28, 2026
NCT ID
NCT05144997About Lorlatinib
Lorlatinib is a approved stage product being developed by Pfizer for Non-Small-Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05144997. Target conditions include Non-Small-Cell Lung Cancer, NSCLC.
What happened to similar drugs?
6 of 20 similar drugs in Non-Small-Cell Lung Cancer were approved
Approved (6) Terminated (6) Active (10)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03127618 | Pre-clinical | Completed |
| NCT03178071 | Pre-clinical | Completed |
| NCT06678555 | Pre-clinical | Active |
| NCT06487078 | Pre-clinical | Recruiting |
| NCT05297890 | Phase 2 | Active |
| NCT05224609 | Phase 1 | Completed |
| NCT05144997 | Approved | Active |
| NCT04753658 | Pre-clinical | Terminated |
| NCT04362072 | Approved | Completed |
| NCT04541706 | Approved | Completed |
| NCT06282991 | Pre-clinical | Completed |
| NCT03909971 | Phase 2 | Completed |
| NCT03542305 | Phase 1 | Completed |
| NCT03505554 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Non-Small-Cell Lung Cancer